![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication June 13, 2007.
Revised July 23, 2007.
Accepted for publication July 25, 2007.
Tamoxifen (TAM) is an anti-estrogen that has been widely used in the treatment and prevention of breast cancer in women. One of the major mechanisms of metabolism and elimination of TAM and its major active metabolites, 4-hydroxy (OH)-TAM and 4-OH-N-desmethyl-TAM (endoxifen), is via glucuronidation. While limited studies have been performed characterizing the glucuronidation of 4-OH-TAM, no studies have been performed on endoxifen.In the present study, characterization of the glucuronidating activities of human UGTs against isomers of 4-OH-TAM and endoxifen was performed. Using homogenates of individual UGT-overexpressing cell lines, UGTs 2B7
1A8 > UGT1A10 exhibited the highest overall O-glucuronidating activity against trans-4-OH-TAM as determined by Vmax/KM, with the hepatic enzyme, UGT2B7, exhibiting the highest binding affinity and lowest KM (3.7 µM). As determined by Vmax/KM, UGT1A10 exhibited the highest overall O-glucuronidating activity against cis-4-OH-TAM, 10-fold higher than the next-most active UGTs 1A1 and 2B7, but with UGT1A7 exhibiting the lowest KM. While both N- and O-glucuronidation occurred for 4-OH-TAM in human liver microsomes, only O-glucuronidating activity was observed for endoxifen; no endoxifen-N-glucuronidation was observed for any UGT tested. UGTs 1A10
1A8 > 2B7 exhibited the highest overall glucuronidating activities as determined by Vmax/KM for trans-endoxifen, with the extra-hepatic enzyme, UGT1A10, exhibiting the highest binding affinity and lowest KM (39.9 µM). Similar to that observed for cis-4-OH-TAM, UGT1A10 also exhibited the highest activity for cis-endoxifen. These data suggest that several UGTs including UGTs 1A10, 2B7 and 1A8 play an important role in the metabolism of 4-OH-TAM and endoxifen.
Key words:
anticancer agents, glucuronidation, HPLC, metabolite kinetics, phase II drug metabolism, UDP glucuronyltransferases
This article has been cited by other articles:
![]() |
J. Tojcic, M.-O. Benoit-Biancamano, M. H. Court, R. J. Straka, P. Caron, and C. Guillemette In Vitro Glucuronidation of Fenofibric Acid by Human UDP-Glucuronosyltransferases and Liver Microsomes Drug Metab. Dispos., November 1, 2009; 37(11): 2236 - 2243. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Olson, R. W. Dellinger, Q. Zhong, D. Sun, S. Amin, T. E. Spratt, and P. Lazarus Functional Characterization of Low-Prevalence Missense Polymorphisms in the UDP-Glucuronosyltransferase 1A9 Gene Drug Metab. Dispos., October 1, 2009; 37(10): 1999 - 2007. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Brauch, T. E. Murdter, M. Eichelbaum, and M. Schwab Pharmacogenomics of Tamoxifen Therapy Clin. Chem., October 1, 2009; 55(10): 1770 - 1782. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Balliet, G. Chen, C. J. Gallagher, R. W. Dellinger, D. Sun, and P. Lazarus Characterization of UGTs Active against SAHA and Association between SAHA Glucuronidation Activity Phenotype with UGT Genotype Cancer Res., April 1, 2009; 69(7): 2981 - 2989. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Blevins-Primeau, D. Sun, G. Chen, A. K. Sharma, C. J. Gallagher, S. Amin, and P. Lazarus Functional Significance of UDP-Glucuronosyltransferase Variants in the Metabolism of Active Tamoxifen Metabolites Cancer Res., March 1, 2009; 69(5): 1892 - 1900. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. O. Dezentje, H.-J. Guchelaar, J. W.R. Nortier, C. J.H. van de Velde, and H. Gelderblom Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer Clin. Cancer Res., January 1, 2009; 15(1): 15 - 21. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Murphy The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984-2008 Drug Metab. Dispos., October 1, 2008; 36(10): 1977 - 1982. [Abstract] [Full Text] [PDF] |
||||